Sanigen's Q1 2026 Net Loss Narrows to 898M Won, Equity Drops and Debt Ratio Rises
- Q1 2026 revenue: 3.31B won (down 21.3% YoY from 4.21B won)
- Operating loss: 0.87B won (improved from 1.19B loss in Q1 2025)
- Net loss: 0.90B won (improved from 1.62B loss in Q1 2025)
- Total equity: 1.59B won (down 35.9% from 2.48B at year-end 2025)
- Net debt ratio: 60.2% (up from 30.3% at year-end 2025)
- Full allowance of 1.40B won for fraud-related receivables
- R&D expenses: 0.38B won (11.6% of revenue)
- Post-report: decided capital increase (~6.57M shares) and 5B won CB issuance
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Quarterly Report (2026.03)
- Company: SANIGEN (188260)
- Submission: SANIGEN Co., Ltd.
- Receipt: 05-14-2026